Skip to main content

Table 3 Adverse drug reactions

From: Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma

   N = 5
   ≥G1 ≥G3
   n (%) n (%)
Any adverse drug reactions 5 (100.0) 5 (100.0)
Clinical findings   
  Nausea 4 (80.0) 2 (40.0)
  Malaise 4 (80.0) 0 (0.0)
  Vomiting 3 (60.0) 0 (0.0)
  Decreased appetite 3 (60.0) 0 (0.0)
  Constipation 3 (60.0) 0 (0.0)
  Oedema peripheral 3 (60.0) 0 (0.0)
  Anaemia 2 (40.0) 2 (40.0)
  Oral discomfort 2 (40.0) 0 (0.0)
  Stomatitis 2 (40.0) 0 (0.0)
  Pyrexia 2 (40.0) 0 (0.0)
  Dysgeusia 2 (40.0) 0 (0.0)
  Headache 2 (40.0) 0 (0.0)
Abnormal laboratory values   
  Neutrophil count decreased 5 (100.0) 5 (100.0)
  Platelet count decreased 4 (80.0) 1 (20.0)
  White blood cell count decreased 4 (80.0) 4 (80.0)
  Alanine aminotransferase increased 2 (40.0) 2 (40.0)
  1. Adverse drug reactions occurring in ≥ 2 subjects are shown
  2. Grade was assessed according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03